NOT that I remotely suggesting it statistically significant at only 15 patients (or being critical of MSB before the usual recriminations start) but MSB's recent GvHD trial reported:
"Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of children or adults with SR-aGVHD who received best available therapy (BAT) or the only approved agent in adults".
CYP reported "Patients treated with CYP-001 had a two-year overall survival rate of 60% (9/15 patients)" by comparison in its small phase 1 trial.
- Forums
- ASX - By Stock
- CYP
- Ann: Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT
Ann: Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT, page-2
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
(20min delay)
|
|||||
Last
22.5¢ |
Change
-0.010(4.26%) |
Mkt cap ! $40.41M |
Open | High | Low | Value | Volume |
23.5¢ | 23.5¢ | 22.5¢ | $11.57K | 49.51K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 100000 | 22.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 7426 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 100000 | 0.220 |
1 | 9761 | 0.210 |
3 | 155000 | 0.200 |
2 | 13135 | 0.195 |
1 | 30000 | 0.190 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 7426 | 1 |
0.240 | 91350 | 1 |
0.250 | 42019 | 2 |
0.275 | 21895 | 1 |
0.280 | 5000 | 1 |
Last trade - 15.43pm 10/05/2024 (20 minute delay) ? |
|
|||||
Last
23.0¢ |
  |
Change
-0.010 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
23.0¢ | 23.5¢ | 23.0¢ | 10710 | ||
Last updated 15.01pm 10/05/2024 ? |
Featured News
CYP (ASX) Chart |